Vascular endothelial growth factor (VEGF) is a process of formation of new blood vessels from endothelial cells or from pre-existing vessels. VEGF’s normal function is during embryonic development, formation of new blood vessels after injury, in muscles after exercise, and as a bypass for a blocked vessel. Overexpression of VEGF can be fatal as they can grow into cancerous cells. VEGF plays both beneficial and damaging roles in organisms. It takes circulating endothelial precursor cells and acts as a growth medium for immature tumor cells. The affinity of VEGF toward endothelial cells is mediated through VEGF-specific tyrosine kinase receptors VEGFR-1, VEGFR-2, and VEGFR-3. Hence, VEGF and its receptors play a major role in the growth of tumor cells. The endotheliotropic property of VEGF causes a major concern for developing vascular endothelial growth factor receptor (VEGFR) inhibitors. The VEGF family in mammals comprises VEGF-A, VEGF-B, VEGF-C, VEGF-D, and PIGF. Out of these, VEGF-A is responsible for angiogenesis and migration and mitosis of endothelial cells. Many therapeutic strategies are developed for inhibiting the signal transduction of VEGF. Some of the therapeutic options are monoclonal antibodies against VEGF or VEGFR, soluble VEGF and VEGFR hybrids, and tyrosine kinase inhibitors.

Vascular endothelial growth factor inhibitors are also termed as angiogenesis inhibitors. They inhibit the growth of new blood vessels. Angiogenesis inhibitors are effective in the treatment of cancer, macular degeneration in the eye, and diseases that involve proliferation of blood vessels. VEGF or angiogenesis is regulated by the activity of endogenous stimulators and inhibitors. Endogenous inhibitors are involved in regulating the process of blood vessel formation. They are derived from cellular matrix and basement protein. Among the factors responsible for angiogenesis, VEGF is the most potent and has high expression in ovarian, endometrial, and cervical cancer. Inhibition of angiogenesis by VEGF requires anti-VEGF/ anti-angiogenesis factors, which reduce the production of pro- angiogenic factors, thereby preventing them from binding to their receptors. The commonly used therapy for VEGF pathway inhibition is monoclonal antibody against VEGF or VEGFR, soluble VEGFR hybrids, and tyrosine kinase inhibitors. Monoclonal antibody Bevacizumab is widely used for treatment.

Global increase in the prevalence of cancer and recognition of therapeutic opportunities offered by oncology treatments have driven the pharmaceutical industry to develop new agents to treat cancer. According to WHO, new cancer cases are expected to rise by 70% in the coming two decades. Approximately 60% of malignant tumors express high concentrations of VEGF. Therefore, therapeutic options to inhibit the VEGF tumor causing pathway has become a major concern for all researchers. One of the factors restraining VEGF inhibitors from becoming a silver bullet in the treatment of cancer is that angiogenesis is not the only factor causing tumors. Other restraints include the side effects caused by VEGF inhibitors such as bleeding and increased blood pressure.

The VEGF inhibitors market can be segmented based on mode of action of the drug, route of administration, end-user, and geography. In terms of mode of action of the drug, the VEGF inhibitors market can be classified into tyrosine kinase inhibitors, monoclonal antibodies, and VEGFR hybrids. Tyrosine kinase inhibitors inhibit the adenosine triphosphate binding sites. Monoclonal antibodies bind to VEGF-A, preventing it from binding to receptors and activating the signaling cascades that lead to angiogenesis. VEGFR hybrids act as decoy receptors and prevent binding of the ligand to its natural receptors. Based on route of administration, the VEGF inhibitors market can be classified into oral and intravenous. In terms of end-user, the VEGF inhibitors market can be divided into hospitals, ambulatory surgical centers, and cancer research institutes. Based on geography, the VEGF inhibitors market can be categorized into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The tyrosine kinase inhibitor segment is a dominant segment of the VEGF inhibitors market in North America, followed by Asia Pacific and Europe. China is projected to drive the VEGF inhibitors market in Asia Pacific by providing expansion opportunities to upcoming companies. Countries such as China, India, and South Asian countries are expected to dominate the VEGF inhibitors market in Asia Pacific. According to WHO, cancer prevalence is estimated to rise at a rapid pace in Africa, Asia, and the U.S.

The top layers in the VEGF inhibitors market are Pfizer, Inc., Novartis AG, AstraZeneca plc, Bayer AG, Merck & Co., Inc., Genentech, Inc. (Roche), Eli Lilly & Company, Sanofi, GlaxoSmithKline plc, Bristol-Myers-Squibb Company, and Boehringer Ingelheim GmbH.

This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.

Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:

  • Customer Experience Maps
  • Insights and Tools based on data-driven research
  • Actionable Results to meet all the business priorities
  • Strategic Frameworks to boost the growth journey

The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.

The following regional segments are covered comprehensively:

  • North America
  • Asia Pacific
  • Europe
  • Latin America
  • The Middle East and Africa

The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.

Below is a snapshot of these quadrants.

1. Customer Experience Map

The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.

2. Insights and Tools

The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.

3. Actionable Results

The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.

4. Strategic Frameworks

The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.

The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:

1. What can be the best investment choices for venturing into new product and service lines?

2. What value propositions should businesses aim at while making new research and development funding?

3. Which regulations will be most helpful for stakeholders to boost their supply chain network?

4. Which regions might see the demand maturing in certain segments in near future?

5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?

6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?

7. Which government regulations might challenge the status of key regional markets?

8. How will the emerging political and economic scenario affect opportunities in key growth areas?

9. What are some of the value-grab opportunities in various segments?

10. What will be the barrier to entry for new players in the market?

With a robust experience in creating exceptional market reports, Transparency Market Research has emerged as one of the trusted market research companies among a large number of stakeholders and CXOs. Every report at Transparency Market Research goes through rigorous research activity in every aspect. The researchers at TMR keep a close watch on the market and extract beneficial growth-boosting points. These points help the stakeholders to strategize their business plans accordingly.

TMR researchers conduct exhaustive qualitative and quantitative research. This research involves taking inputs from the experts in the market, focused attention on recent developments, and others. This method of research makes TMR stand out from other market research firms.

Here's how Transparency Market Research helps the stakeholders and CXOs through the reports:

Inculcation and Evaluation of Strategic Collaborations: The TMR researchers analyze recent strategic activities like mergers, acquisitions, partnerships, collaborations, and joint ventures. All the information is compiled and included in the report.

Perfect Market Size Estimations: The report analyzes the demographics, growth potential, and capability of the market through the forecast period. This factor leads to the estimation of the market size and also provides an outline about how the market will retrieve growth during the assessment period.

Investment Research: The report focuses on the ongoing and upcoming investment opportunities across a particular market. These developments make the stakeholders aware of the current investment scenario across the market.

Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.

Custom Market Research Services

TMR offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.


Vascular Endothelial Growth Factor Inhibitors Market

Pre Book